Market Overview:
The global pharmaceutical asset management market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of counterfeit drugs, rising demand for better supply chain management, and growing investments in R&D by pharmaceutical companies. The hardware segment is expected to dominate the global pharmaceutical asset management market during the forecast period. This can be attributed to the increasing demand for track-and-trace solutions and RFID tags for better inventory tracking and anti-counterfeiting measures.
Product Definition:
Pharmaceutical asset management is the proactive and strategic approach to managing pharmaceutical products and services through their life-cycle with the goal of optimizing value. Pharmaceutical Asset Management (PAM) integrates all aspects of product planning, development, and life-cycle management into a cohesive strategy in order to achieve business objectives.
The importance of Pharmaceutical Asset Management cannot be overstated as it can have a significant impact on a company's bottom line. By employing sound PAM principles, companies can improve operational efficiency, optimize inventory levels, reduce waste and ultimately improve profitability.
Hardware(Pharma Asset):
Hardware is a collection of physical assets which are used to perform a specific function in the pharmaceutical industry. It includes items such as computers, laptops, tablets, scanners & printers and other electronic devices. Hardware is an important aspect for any pharma company as it helps them to save time and reduce operational costs by streamlining workflow processes.
Software(Pharma Asset):
Software is used in pharmaceutical asset management for various functions such as maintenance, analytics, and reporting. It also helps to improve the overall efficiency of the system by providing a centralized platform for all kind of information related to assets.
The global software market was valued at USD 45 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period.
Application Insights:
The anti-drug counterfeiting application segment led the global pharmaceutical asset management market in 2017. This is attributed to the increasing prevalence of drug counterfeiting, which has resulted in a growing demand for anti-counterfeiting technologies and solutions. For instance, according to an article published by The Pharmaceutical Journal (2016), it was estimated that around 25% of all drugs sold online are counterfeit. In addition, according to data published by WHO concerning international drug trade, approximately USD 305 billion worth of medicines were traded across international borders in 2016.
Pharmaceutical companies are increasingly deploying technologies such as RFID and barcodes on pharmaceutical products that help identify if the product has been tampered with or not during distribution as well as storage processes at different levels within a supply chain network.
Regional Analysis:
Asia Pacific pharmaceutical asset management market is anticipated to grow at a lucrative rate over the forecast period. The growth can be attributed to increasing healthcare spending, rising adoption of advanced technologies in developing countries such as India and China, and growing need for better inventory control systems in these markets. In addition, factors such as favorable government initiatives pertaining to digitization of records are expected to drive demand for AM solutions over the forecast period.
North America pharmaceutical asset management (PAM) market is projected to witness significant growth during the forecast years owing to high investments made by governments towards improving healthcare infrastructure coupled with stringent regulatory framework aimed at ensuring patient safety & quality standards within an organization’s assets throughout their lifecycle cycle.
Growth Factors:
- Increasing demand for generic drugs due to their low cost and efficacy as compared to branded drugs
- Rising prevalence of chronic diseases such as cancer, diabetes, and heart diseases that require long-term treatment
- Growing number of patent expiries of blockbuster drugs in the next few years
- Proliferation of specialty pharmacies that focus on complex drug therapies for niche patient populations
- Emergence of new technologies such as real-world evidence and machine learning that can improve decision making around pharmaceutical asset management
Scope Of The Report
Report Attributes
Report Details
Report Title
Pharmaceutical Asset Management Market Research Report
By Type
Hardware(Pharma Asset), Software(Pharma Asset)
By Application
Anti-drug Counterfeiting, Supply Chain Management
By Companies
McKesson Corporation, Cerner Corporation, Siemens Healthcare, GE Healthcare, Allscripts, Epic System, IBM Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
137
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Pharmaceutical Asset Management Market Report Segments:
The global Pharmaceutical Asset Management market is segmented on the basis of:
Types
Hardware(Pharma Asset), Software(Pharma Asset)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-drug Counterfeiting, Supply Chain Management
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- McKesson Corporation
- Cerner Corporation
- Siemens Healthcare
- GE Healthcare
- Allscripts
- Epic System
- IBM Corporation
Highlights of The Pharmaceutical Asset Management Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hardware(Pharma Asset)
- Software(Pharma Asset)
- By Application:
- Anti-drug Counterfeiting
- Supply Chain Management
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharmaceutical Asset Management Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pharmaceutical asset management is a specialized form of investment management that focuses on the acquisition, preservation, and distribution of pharmaceutical assets. Pharmaceutical asset managers typically work with pharmaceutical companies to identify and invest in promising new drugs and medical technologies. They also help companies manage their overall portfolios of drug products, research and development projects, manufacturing facilities, and other assets related to the pharmaceutical industry.
Some of the major companies in the pharmaceutical asset management market are McKesson Corporation, Cerner Corporation, Siemens Healthcare, GE Healthcare, Allscripts, Epic System, IBM Corporation.
The pharmaceutical asset management market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharmaceutical Asset Management Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pharmaceutical Asset Management Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pharmaceutical Asset Management Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pharmaceutical Asset Management Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pharmaceutical Asset Management Market Size & Forecast, 2018-2028
4.5.1 Pharmaceutical Asset Management Market Size and Y-o-Y Growth
4.5.2 Pharmaceutical Asset Management Market Absolute $ Opportunity
Chapter 5 Global Pharmaceutical Asset Management Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pharmaceutical Asset Management Market Size Forecast by Type
5.2.1 Hardware(Pharma Asset)
5.2.2 Software(Pharma Asset)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pharmaceutical Asset Management Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pharmaceutical Asset Management Market Size Forecast by Applications
6.2.1 Anti-drug Counterfeiting
6.2.2 Supply Chain Management
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pharmaceutical Asset Management Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pharmaceutical Asset Management Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pharmaceutical Asset Management Analysis and Forecast
9.1 Introduction
9.2 North America Pharmaceutical Asset Management Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pharmaceutical Asset Management Market Size Forecast by Type
9.6.1 Hardware(Pharma Asset)
9.6.2 Software(Pharma Asset)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pharmaceutical Asset Management Market Size Forecast by Applications
9.10.1 Anti-drug Counterfeiting
9.10.2 Supply Chain Management
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pharmaceutical Asset Management Analysis and Forecast
10.1 Introduction
10.2 Europe Pharmaceutical Asset Management Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pharmaceutical Asset Management Market Size Forecast by Type
10.6.1 Hardware(Pharma Asset)
10.6.2 Software(Pharma Asset)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pharmaceutical Asset Management Market Size Forecast by Applications
10.10.1 Anti-drug Counterfeiting
10.10.2 Supply Chain Management
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pharmaceutical Asset Management Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pharmaceutical Asset Management Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pharmaceutical Asset Management Market Size Forecast by Type
11.6.1 Hardware(Pharma Asset)
11.6.2 Software(Pharma Asset)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pharmaceutical Asset Management Market Size Forecast by Applications
11.10.1 Anti-drug Counterfeiting
11.10.2 Supply Chain Management
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pharmaceutical Asset Management Analysis and Forecast
12.1 Introduction
12.2 Latin America Pharmaceutical Asset Management Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pharmaceutical Asset Management Market Size Forecast by Type
12.6.1 Hardware(Pharma Asset)
12.6.2 Software(Pharma Asset)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pharmaceutical Asset Management Market Size Forecast by Applications
12.10.1 Anti-drug Counterfeiting
12.10.2 Supply Chain Management
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pharmaceutical Asset Management Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pharmaceutical Asset Management Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pharmaceutical Asset Management Market Size Forecast by Type
13.6.1 Hardware(Pharma Asset)
13.6.2 Software(Pharma Asset)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pharmaceutical Asset Management Market Size Forecast by Applications
13.10.1 Anti-drug Counterfeiting
13.10.2 Supply Chain Management
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pharmaceutical Asset Management Market: Competitive Dashboard
14.2 Global Pharmaceutical Asset Management Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 McKesson Corporation
14.3.2 Cerner Corporation
14.3.3 Siemens Healthcare
14.3.4 GE Healthcare
14.3.5 Allscripts
14.3.6 Epic System
14.3.7 IBM Corporation
